0001209191-23-000358.txt : 20230103 0001209191-23-000358.hdr.sgml : 20230103 20230103174056 ACCESSION NUMBER: 0001209191-23-000358 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221229 FILED AS OF DATE: 20230103 DATE AS OF CHANGE: 20230103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEVIN ARTHUR A CENTRAL INDEX KEY: 0001181556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39321 FILM NUMBER: 23503521 MAIL ADDRESS: STREET 1: 1896 RUTHERFORD ROAD CITY: CARLSBAD STATE: CA ZIP: 92008 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Avidity Biosciences, Inc. CENTRAL INDEX KEY: 0001599901 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461336960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE STREET 2: SUITE 125 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-401-7900 MAIL ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE STREET 2: SUITE 125 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Avidity Biosciences LLC DATE OF NAME CHANGE: 20161227 FORMER COMPANY: FORMER CONFORMED NAME: Avidity NanoMedicines LLC DATE OF NAME CHANGE: 20140211 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-29 0 0001599901 Avidity Biosciences, Inc. RNA 0001181556 LEVIN ARTHUR A C/O AVIDITY BIOSCIENCES, INC. 10578 SCIENCE CENTER DRIVE, SUITE 125 SAN DIEGO CA 92121 0 1 0 0 Chief Scientific Officer Common Stock 2022-12-29 4 M 0 40000 1.24 A 41330 D Common Stock 2022-12-29 4 S 0 40000 22.0142 D 1330 D Stock Option (Right to Buy) 1.24 2022-12-29 4 M 0 40000 0.00 D 2030-02-18 Common Stock 40000 88423 D The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.16. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter. /s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact 2023-01-03